MARKET

RGNX

RGNX

Regenxbio
NASDAQ
19.72
+1.16
+6.25%
After Hours: 19.72 0 0.00% 16:04 06/02 EDT
OPEN
19.56
PREV CLOSE
18.56
HIGH
19.77
LOW
18.67
VOLUME
339.33K
TURNOVER
0
52 WEEK HIGH
35.73
52 WEEK LOW
17.02
MARKET CAP
857.15M
P/E (TTM)
-3.1575
1D
5D
1M
3M
1Y
5Y
Baird Initiates Coverage of Regenxbio (RGNX) with Outperform Recommendation
NASDAQ · 1d ago
Regenxbio: Statement of changes in beneficial ownership of securities
Press release · 1d ago
The Latest Analyst Ratings for Regenxbio
Benzinga · 1d ago
Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2023
Benzinga · 1d ago
Baird Initiates Coverage On Regenxbio with Outperform Rating, Announces Price Target of $42
Benzinga · 1d ago
Baird Initiates REGENXBIO at Outperform With $42 Price Target
Baird Initiates REGENXBIO at Outperform With $42 Price Target
MT Newswires · 1d ago
Regenxbio's gene therapy for Hunter syndrome gets FDA regenerative medicine status
Seeking Alpha · 05/23 12:00
REGENXBIO Secures FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For RGX-121 Gene Therapy For Hunter Syndrome
Benzinga · 05/23 11:06
More
About RGNX
REGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RGNX stock methods without spending real money on the virtual paper trading platform.